MEDP is trading 5.7% down at $515.00 after Jefferies downgraded the stock from Buy to Hold, citing a stretched valuation and significant downside risk.
- Analysts highlighted a disconnect between the current share price and achievable fundamentals, noting a depleted reservoir of potential bookings.
- Biotech funding pressures and a broader risk-off market sentiment are further weighing on the stock's performance.